The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals

Neuroscience and Behavioral Physiology

Volumn 33, Issue 3, 2003, Pages 273-278

  Rukoyatkina, N I ^a   Gorbunova, L V ^a   Gmiro, V E ^b   Lukomskaya, N Ya ^a  

^a SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

AMPA receptors; Catelepsy; Convulsions; Glutamate antagonists; NMDA receptors; Parkinsonism

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; HALOPERIDOL; IEM 1921; IEM 1922; KAINIC ACID; MEMANTINE; N (5 AMMONIOPENTYL) 1 PHENYLCYCLOHEXYLAMMONIUM DIBROMIDE; N METHYL DEXTRO ASPARTIC ACID; PHENYLCYCLOHEXYL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; BODY MOVEMENT; CATALEPSY; CLONIC SEIZURE; COMPARATIVE STUDY; CONVULSION; CORRELATION ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EXPERIMENTAL MODEL; IN VIVO STUDY; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; RAT; RECEPTOR BLOCKING; TONIC CLONIC SEIZURE;

ANIMALS; ATAXIA; BEHAVIOR, ANIMAL; CATALEPSY; DIAMINES; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; KAINIC ACID; MEMANTINE; MICE; MICE, INBRED STRAINS; N-METHYLASPARTATE; QUATERNARY AMMONIUM COMPOUNDS; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 0038079319     PISSN: 00970549     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022107516333     Document Type: Article

References (23)

1. L. G. Magazanik, K. V. Bol'shakov, S. L. Buldakova, V. E. Gmiro, N. A. Dorofeeva, N. Ya. Lukomskaya, N. N. Potep'eva, M. V. Samoilova, D. B. Tikhonov, I. M. Fedorova, and E. V. Frolova, "Structural characteristics of ionotropic glutamate receptors, identified by channel blockade," Ros. Fiziol. Zh. im. I. M. Sechenova, 86, 1138-1151 (2000).
2. N. I. Rukoyatkina, L. V. Gorbunova, V. E. Gmiro, and N. Ya. Lukomskaya, "The ability of glutamate receptor antagonists to ameliorate experimental catalepsy in rats," Ros. Fiziol. Zh. im. I. M. Sechenova, 86, No. 6, 626-634 (2000).
3. A. Bissago, P. Krzascik, E. Jankowska, W. Palejko, W. Kostowski, and W. Danysz, "Effect of glutamate receptor antagonists on NMDA- and AMPA-induced convulsant effects in mice and rats," Eur. J. Pharmacol., 242, 213-220 (1993).
4. W. Danysz and C. G. Parsons, "N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications," Pharmacol. Rev., 50, 597-664 (1998).
5. P. J. Elliott, S. P. Close, D. M. Walsh, A. G. Hayes, and A. S. Marriott, "Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists," J. Neural. Transm., (Section P-D), 2, 91-100 (1990).
6. M. Gossel, W. J. Schmidt, W. Loscher, W. Zajaczkowski, and W. Danysz, "Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats," J. Neural Transm., (Section P-D), 10, No. 1, 27-39 (1995).
7. J. T. Greenamyre and R. H. P. Porter, "Anatomy and physiology of glutamate in CNS," Neurology, 44, Suppl. 8, S7-S13 (1994).
8. T. Klockgether, L. Turski, T. Honore, Z. Zhang, D. M. Gash, R. Kurlan, and J. T. Greenamyre, "The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys," Ann. Neurol., 30, 717-723 (1991).
9. P.-A. Loschmann, K. W. Lange, M. Kunow, K.-J. Rettig, P. Jahnig, T. Honore, L. Turski, H. Wachtel, P. Jenner and C. D. Marsden, "Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease," J. Neural Transm., (Section P-D), 3, 203-213 (1991).
10. 2 agonists in rat model of Parkinson's disease," Synapse, 26, No. 4, 381-391 (1997).
11. M. R. Luquin, J. A. Obeso, J. Laguna, J. Guillen, and J. M. Martinez-Lage, "The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys," Eur. J. Pharmacol., 235, 297-300 (1993).
12. L. G. Magazanik, S. L. Buldakova, M. V. Samoilova, V. E. Gmiro, I. R. Mellor, and P. N. R. Usherwood, "Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives," J. Physiol. (London), 505, 655-663 (1997).
13. J. May, Z. Rogoz, G. Skuda, and T. Jaros, "Some behavioral effects of CNQX and NBQX, AMPA receptor antagonists," Pol. J. Pharmacol., 47, No. 4, 269-277 (1995).
14. A. Mele, D. N. Thomas, and A. Pert, "Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity," Neurosci., 82, No. 1, 43-58 (1998).
15. 2-mediated behavior in the 6-hydroxydopamine model of turning: Relationship with c-fos expression," J. Pharmacol. Exp. Ther., 260, 402-408 (1992).
16. K. Ossowska, "The role of excitatory amino acids in experimental models of Parkinson's disease," J. Neural Transm. (section P-D), 8, No. 1-2, 39-71 (1994).
17. C. G. Parsons, W. Danysz, and G. Quack, "Glutamate in CNS disorders as target for drug development: An update," Drugs News Prospects, 11, No.9, 523-569 (1998).
18. C. D. Parsons, W. Danysz, and G. Quack, "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data," Neuropharmacol., 38, 735-767 (1999).
19. J. J. Schuller and J. F. Marshall, "Intrastriatal DNQX induces rotation and pallidal fos in the 6-OHDA model of Parkinson's disease," Neuroreport, 6, No. 18, 2594-2608 (1995).
20. B. Stauch-Slusher, K. C. Rissolo, K. F. Anzilotti, Jr., and P. F. Jackson, "Centrally administrated AMPA antagonists increase locomotion in parkinsonian rats," J. Neural Transm. (setion P-D), 9, No. 2-3, 145-149 (1995).
21. R. D. Sturgeon, R. G. Fessler, and H. Y. Meltzer, "Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats," Eur. J. Pharmacol., 59, 169-179 (1979).
22. D. B. Tikhonov, M. V. Samoilova, S. L. Buldakova, V. E. Gmiro, and L. G. Magazanik, "Voltage-dependent block of native AMPA receptor channels by dicationic compounds," Brit. J. Pharmacol., 126, 265-274 (2000).
23. L. Verhagen-Metman, P. Del-Dotto, P. Van Den Munckhof, J. Fang, M. M. Mouradien, and T. N. Chase, "Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease," Neurology, 50, No. 5, 1323-1326 (1998).